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Potassium supplementation ameliorates
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Potassium supplementation ameliorates mineralocorticoid-induced so-
dium retention. Potassium depletion induced by dietary potassium
restriction causes sodium retention while potassium supplementation
augments urinary sodium excretion. The role of external potassium
balance in modulating mineralocorticoid-induced sodium retention in
humans is unknown. Accordingly, eight healthy subjects were studied
at the Clinical Research Center receiving a constant diet providing (per
kg body wt) sodium 2.5 mmol, potassium 1.1 mmol daily. After
establishing basal sodium and potassium balance over three days, each
subject received 9a-fiudrocortisone 0.4 mg/day for 10 days. Subjects
were studied twice, four to eight weeks apart, in a double blind,
randomized crossover design receiving either placebo or additional KCI
(80 mmollday) over the 10 day study period. Serum potassium concen-
trations were unchanged from basal values on KC1 while the values fell
(4.1 0.1 vs. 3.4 0.1 mmol/liter, P = 0.01) on placebo. Urinary
sodium excretion decreased with fiudrocortisone administration in both
groups, but this decrease reached significance only in the placebo
group. Furthermore, during fludrocortisone administration the sodium
excretion rates on KC1 were significantly higher compared to the values
noted on placebo (134 8 vs. 112 13 mmol/day, P = 0.01). Body
weight recorded after 10 days of fiudrocortisone administration was
higher on placebo compared to KCI (72.3 2.8 vs. 71.6 2.8 kg, P =
0.01). Plasma renin activity, and aldosterone concentrations decreased
on fludrocortisone while atrial natriuretic peptide levels increased.
These studies suggest that amelioration of hypokalemia attenuates
mineralocorticoid-induced sodium retention. Therefore, potassium de-
pletion may contribute to the mineralocorticoid-induced sodium reten-
tion.
Studies in humans and experimental animals suggest that
potassium intake is a critical determinant of urinary sodium
excretion [1—5]. Augmented potassium intake enhances urinary
sodium excretion while lowering the intake of this cation exerts
the opposite effect [4—8]. Acute potassium loading in humans
produces natriuresis lasting for several hours [8]. Bauer and
Gaunter observed a dose dependent increase in urinary sodium
excretion when potassium intake was increased from 0 to 300
mmollday in healthy volunteers [4]. Lennon and Lemann ob-
served that potassium depletion induced by the administration
of ammonium chloride enhances fractional sodium reabsorption
in normal subjects [3]. Natriuretic effects of potassium have
also been demonstrated in dogs and rats [5, 9].
We have recently demonstrated that even mild potassium
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depletion produces striking alterations in urinary sodium excre-
tion in normotensive and hypertensive subjects [6, 10, 11].
These sodium retentive effects of potassium depletion are
observed at normal as well as low sodium intake. Mineralocor-
ticoid administration in humans produces potassium depletion,
hypokalemia and sodium retention [12—17]. We hypothesized
that potassium supplementation would attenuate the mineralo-
corticoid-induced sodium retention. To test this hypothesis we
administered 9a-fludrocortisone to a group of healthy subjects
in combination with either placebo or potassium chloride (KCI).
We characterized the changes in plasma and urinary electro-
lytes, circulating natriuretic hormones and renal hemodynamics
during both study periods.
Methods
Study subjects
Eight healthy normotensive subjects, including one female,
were studied. Complete medical history, physical examination,
and a biochemical and hematologic profile were obtained to
determine the eligibility for participation in the study. The
subjects were aged 23 to 44 years and were receiving no
medications at the time of the study. Dietary history was
obtained to determine the subjects' food habits and to estimate
their usual sodium and potassium intake. An informed consent
which had been approved by the institutional committee on
human research was obtained from each subject.
Study protocol
All the subjects were studied at the Clinical Research Center
(CRC) for a period of 15 days on two separate occasions.
During the study period the subjects received all their meals at
the CRC. The menu for each subject was prepared based upon
individual food preferences. The diet was kept constant for
each subject through the entire study. Subjects were required to
ingest the entire food allotment in a 24 hour period. These
constant diets provided approximately 2.5 mmol sodium, 1.1
mmol potassium, 1.6 g protein, 35 Kcal energy, 15 mg calcium,
21 nig phosphorus, 4.5 mg magnesium, per kg body weight
daily, Water intake was not restricted and the subjects were
encouraged to maintain their usual activities. After three days
(baseline period) of equilibration on the study diet subjects
received 9a-fludrocortisone 0.4 mg/day in four divided doses for
a period of 10 days (study period). This dose of fludrocortisone
is well tolerated and has been previously shown to induce
sodium retention and potassium depletion [12, 14, 15, 17]. In a
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double-blind randomized, crossover design subjects received
either placebo or 80 mmol/day of additional KC1. We estimated
that 80 mmol/day of potassium is required to offset the ongoing
potassium losses from fludrocortisone administration. In addi-
tion, we have previously observed that this dose of KC1 is well
tolerated [6, 10, 11]. We chose to administer the chloride salt of
potassium in order to assure adequate repletion of potassium
stores while the subjects were receiving fiudrocortisone. Ad-
ministration of organic salts of potassium which get metabo-
lized to bicarbonate as well as administration of potassium
bicarbonate may worsen the hyperbicarbonatemia induced by
fludrocortisone. Augmented bicarbonate filtration may obligate
distal potassium secretion and thus prevent sufficient repletion
of potassium stores. Both placebo and KC1 were administered
in four doses along with fiudrocortisone. Net potassium intake
on placebo averaged 80 mmollday and on KC1 160 mmol/day.
After 10 days of fludrocortisone administration both the miner-
alocorticoid and the supplements (placebo/KC1) were discon-
tinued and the subjects were observed for additional two days
while still ingesting the constant diets (recovery period).
After a two to eight week washout period each subject was
readmitted into the study for a 15-day period of second arm
(placebo/KCI). Thus each subject was studied on two different
occasions acting as his/her own control. Although the diets
varied slightly between subjects, the menu was kept constant
for each subject through the entire study. None of the subjects
experienced any side effects during the study.
Measurements
During the entire study 24-hour urine samples were obtained
daily. Urine samples were analyzed for measurement of so-
dium, potassium and creatinine. Body weight was recorded
daily with regular clothing and without shoes. Blood pressure
was recorded each morning as previously described [11]. At the
end of baseline period as well as at the end of study period,
glomerular filtration rate and renal plasma flow were estimated
by measuring the clearances of inulin and PAH. The methods
employed for clearance measurements were described in our
previous publications [11, 18]. Briefly, after administering a
water load of 10 mI/kg body weight, primed continuous infusion
of inulin and PAH were maintained to attain plasma concentra-
tions of 20 mg/dl and 2.0 mg/dl, respectively. Subjects ingested
additional 250 ml of water at hourly intervals. Following a
two-hour equilibration period, three urine samples were ob-
tained by spontaneous voiding at 60 minute intervals. Plasma
samples were obtained during the midpoint of urine collection
and the clearance was calculated using the standard formula
(UV/P). At the initiation and termination of fludrocortisone
administration supine blood samples were obtained in a fasting
state. These samples were analyzed for serum biochemical
profile and plasma hormonal assays described below. In addi-
tion, on days 4 and 7 of fludrocortisone administration serum
samples were obtained for the measurement of potassium
concentrations.
Laboratory methods
The methods used in the biochemical and radioimmunoas-
says are described in previous publications from our laboratory
[11, 18, 19]. Plasma renin activity, aldosterone, insulin and
arginine vasopressin levels were measured by radioimmunoas-
say. Intact parathyroid hormone concentrations in the plasma
were measured by a radioimmunometric assay (Incstar Corpo-
ration, Stiliwater, Minnesota, USA). Blood samples for endo-
thelin and atrial natriuretic peptide were collected into chilled
syringes and transferred into polypropylene tubes containing
EDTA (1 mglml) and aprotinin (500 KIU/ml) at 0°C. Following
centrifugation at 3000 x g for 15 minutes plasma was separated.
The plasma samples were stored at —70°C until assay. The
plasma was acidified by adding trifluoroacetic acid and then run
through an activated C-18 SEP-COLUMN. Endothelin and
atrial natriuretic peptide were eluted from the column with
acetonitrile and trifluoroacetic acid. Eluant was evaporated to
dryness in a centrifugal concentrator and the residue was
dissolved in an RIA buffer. Samples with recovery rates ex-
ceeding 60% were subjected to RIA by using an RIA Kit
(Peninsula Laboratories, Belmont, California, USA). Urine
sodium and potassium were measured on a flame photometer
(Model 143, Instrumentation Laboratory, Lexington, Massa-
chusetts, USA) and creatinine was measured by a colorimetric
method. Cumulative sodium balance was calculated from the
baseline urinary sodium excretion and the change in excretion
rates during fludrocortisone administration. Serum electrolytes
and biochemical profile were measured on EKTACHROME
Analyzer (Kodak Company, West Chester, New York, USA).
Inulin and PAH in the plasma and urine were measured by
standard chemical methods.
Data analysis
Each subject participated in both treatment protocols (place-
bo and KC1) and thus acted as own control. The effect of time
and treatment were ascertained by repeated measures analysis
of variance [20]. In paired samples, the distribution of the
sample was determined by Wilk-Shapiro test and the difference
from pre-study values or the difference between the two treat-
ments was then established by the paired t-test or the signed
rank test as applicable [211. A two-tailed P value less than 0.05
was considered significant. Serum biochemical profiles from
eight subjects and complete balance data and hormonal data
from seven subjects were available for analysis. CLINFO,
BMDP and SAS software packages were used for data storage
and analysis. Data are expressed as mean SEM.
Results
Alterations in urinary excretion rates for sodium and potas-
sium are illustrated in Figure 1. In order to elucidate the effect
of potassium on the retentive and escape periods of sodium
excretion during fludrocortisone administration, we divided the
study period into early (days 1 to 5) and late phases (days 6 to
10). Baseline urinary potassium excretion rates were similar in
the two groups prior to randomization (68 7 mmolJday prior
to placebo vs. 66 6 mmollday prior to KC1). In the placebo
group urinary potassium excretion rose significantly (P = 0.03)
during early phase of fludrocortisone administration to 81 7
mmollday. Although the excretion rates returned to near base-
line values (71 5 mmollday) during late phase, these values
represent inappropriate potassium wasting in the setting of
hypokalemia. These urinary losses combined with augmented
stool losses have resulted in substantial depletion of body's
potassium stores as evidenced by a decrease in serum potas-
sium concentration (see below). An avid potassium retention
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Fig. 1. Changes in urinary potassium excretion (A) and urinary sodium
excretion (B) in subjects receiving fludrocortisone 0.4 mg/day along
with cit her placebo (•)orpotassium chloride () during a 10 day study
period. Baseline and recovery values were obtained before and after the
study period respectively. P value represents significant differences
between placebo and potassium chloride (KC1) by paired comparison
was noted during recovery, with the urinary excretion rates
decreasing significantly (F = 0.004) below the basal levels.
When the subjects received KCI, urinary potassium excretion
during the study period was significantly higher compared to the
values noted on placebo. During recovery potassium excretion
on KCI returned to basal levels suggesting that the subjects
maintained adequate body stores of potassium despite the
administration of fiudrocortisone.
Serum potassium concentrations (mmollliter) were similar at
baseline in the placebo (4.1 0.1) and KC1 (3.9 0.1) groups.
During fiudrocortisone administration serum potassium concen-
trations (mmolfliter) decreased significantly (P 0.007) from
baseline levels in the placebo group (3.8 0.1 on day 4; 3.7
0.1 on day 7; 3.4 0.1 on day 10) while there were no significant
alterations in serum potassium concentrations on KC1 (4.1
0.1 on day 4; 4.0 0.1 on day 7; 3.8 0.1 on day 10).
Furthermore, the levels observed on days 4, 7 and 10 of the
study period were significantly (P = 0.02) lower on placebo
compared to the corresponding values observed on KCI.
Basal urinary sodium excretion rates were similar in the two
study groups prior to randomization (156 11 vs. 150 13
mmollday; Fig. 1). Urinary sodium excretion decreased
promptly in response to fludrocortisone when the subjects
received placebo. Excretion rates observed during early (P =
0.007) as well as late phases (F 0.01) were significantly lower
compared to baseline values. When the subjects received KC1,
urinary sodium excretion decreased slightly from baseline val-
ues during the early phases, but this decrease did not reach
statistical significance (P = 0.1). The excretion rates on KC1
returned to basal levels during the late phase. Sodium excretion
on KC1 was significantly higher than the values observed on
placebo during both early and late phases of fiudrocortisone
administration. The average sodium excretion for the 10-day
study period on KCI was significantly higher than the values
noted on placebo (135 10 vs. 112 13 mmoL/day,P = 0.001).
Even at the end of 10-day study period urinary sodium excre-
tion rates on KC1 (175 15 mmollday) were significantly (P
0.01) higher than the rates noted on placebo (134 20 mmol/
day). Urinary sodium excretion rates during recovery were
similar between the groups, but in each group values were
significantly higher than the corresponding baseline levels (P =
0.005). This enhanced natriuresis during recovery period fur-
ther confirms the extracellular fluid volume (ECF) volume
expansion during mineralocorticoid administration during both
study periods. Urinary creatinine excretion during the study
period was similar between placebo and KC1 (1784 121 vs.
1711 107 mg/day).
Changes in cumulative sodium balance and body weight are
illustrated in Figure 2. While the cumulative sodium balance on
potassium supplements reached a plateau by day 6, small
additional amounts of sodium continued to accrue on placebo.
Baseline body weight was similar in the two groups (70.3 3.0
vs. 70.3 2.7 kg). Concurrent with the sodium retention, body
weights increased significantly (F 0.0001) in both groups.
These measurements reached significantly (P = 0.02) higher
levels on placebo compared with potassium. It is of interest to
note that despite striking differences in sodium balance, during
the first five days of the study period the increase in body
weight was similar between the two study groups. During the
placebo studies part of the retained sodium must have entered
the cells to replace the lost potassium. In contrast, the potas-
sium rich cells in the KC1-treated group warranted no such
transcellular sodium shifts. Therefore, all the retalned sodium
might have been entrapped in the extracellular compartment.
Measurement of these compartmental volumes would have
assisted in the verification of this possibility. Unfortunately, the
techniques currently available for testing in humans lack the
sensitivity needed to detect minor differences in volume. The
discrepancy between cumulative sodium retention (426 mmol)
and gain in body weight (2 kg) on placebo can also be attributed
to the loss of potassium in the urine (80 mmol) and stool
(approximately 40 to 50 mmol). In contrast, while potassium
stores were unchanged on KC1, cumulative sodium retention
(170 mmol) closely paralleled the galn in body weight (1.3 kg).
In response to fiudrocortisone administration, plasma renin
activity and plasma aldosterone concentrations decreased,
while plasma atrial natriuretic peptide concentrations increased
(Table 1). Because insulin, parathyroid hormone and endothelin
have been shown to modulate urinary sodium excretion, we
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A Cumulative sodium balance water our subjects manifested a 4 mmol/liter increase in serum
sodium concentration, and this increase was identical between
placebo and KCI studies. The increase in sodium concentration
was accompanied by equivalent increases in measured plasma
osmolality from baseline values in both placebo (292 I vs. 297
2 mmoilkg) and KCI (290 1 vs. 297 2 mmollkg) studies.
None of the subjects complained of an increase in thirst during
the study period. Plasma arginine vasopressin concentrations
were unchanged during fludrocortisone administration in both
study groups (Table 1). Although the modest increase in plasma
osmolality fell below the threshold for thirst stimulation, even
small increases in tonicity would be expected to stimulate
vasopressin concentrations [22]. This relative suppression of
vasopressin concentration in the context of an increase in
sodium concentration may be consequent to the expansion of
ECF during fludrocortisone administration. We observed no
significant change in total urine volume during fludrocortisone
administration.
Biochemical profile revealed a significant decrease in serum
albumin concentration during fludrocortisone administration
2 3 4 5 6 7 8 9 10 (Table 2). The decrease in albumin concentration was accom-
panied by parallel decreases in total serum calcium concentra-
Time, days tion. Serum total CO2 levels increased when subjects received
fludrocortisone with placebo, but these differences did not
reach significance. These CO2 levels were unchanged when
subjects received fiudrocortisone with KC1. Serum urea nitro-
gen concentrations decreased in both groups but reached sig-
nificance only in the placebo group. The alterations in these
biochemical values were in accord with the modest ECF
volume expansion induced by fludrocortisone. Even though
fludrocortisone induced ECF volume expansion, we observed
no significant change in blood pressure in these normotensive
subjects. Volume-induced increases in blood pressure might
have been neutralized by the simultaneous suppression of renin
and elevation in atnal natriuretic peptide levels.
Discussion
Our studies suggest that potassium intake is a critical deter-
minant of mineralocorticoid-induced sodium retention as well
as mineralocorticoid escape. To our knowledge this is the first
demonstration in humans that establishes a role for potassium
in modulating mineralocorticoid-induced sodium retention.
Various hemodynamic, hormonal and neurogenic factors have
been implicated in the mediation of mineralocorticoid escape
[23, 24]. Increase in renal perfusion pressure, suppression of the
renin-angiotensin system and stimulation of atrial natriuretic
peptide have been proposed as the principal mediators of
escape. Hall et al observed that dogs receiving aldosterone
failed to escape if their renal perfusion pressure is kept constant
[25]. Suppression of renin activity and stimulation of atrial
natriuretic peptide activity are temporally related to escape [17,
24]. Gillard et al observed that escape is accompanied by a
potentiation of the natriuretic effect of atrial natriuretic peptide
[14]. Our current studies indicate that potassium-induced mod-
ulation of mineralocorticoid escape occurs independently of
changes in systemic arterial pressure, renin-angiotensin system
and circulating atnal natriuretic peptide concentrations.
The directional changes in plasma concentrations of vasoac-
tive hormones confirm the expansion of ECF volume during
fludrocortisone administration. However, it is of interest to
400 -
300 -
200 —
100 -
0—
B Body weight
0
E
E
0)
72 -
70
1 2 3 4 5 6 7 8 9 10
Time, days
Fig. 2. Changes in cumulative sodium balance (A) and body weight (8)
in subjects receiving fludrocortisone 0.4 mg/day along with either
placebo (0) orpotassium chloride (U) for 10 days. P value represents
significant differences between placebo and potassium chloride (KC1).
For clarity SEM is not shown.
measured plasma concentrations of these hormones but de-
tected no significant alterations during fludrocortisone adminis-
tration (Table 1). We observed no significant differences in the
clearances of inulin and PAH during fludrocortisone adminis-
tration.
Sodium retention during fludrocortisone administration was
accompanied by small but consistent elevations in serum so-
dium concentrations (Figure 3). Despite unrestricted access to
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Table 1. Hormonal and renal hemodynamic measurements obtained at baseline and after 10 days of fludrocortisone administration
Baseline
Fludrocortisone
+ placebo Baseline
Fludrocortisone
+ KCI
Plasma levels
Renin activity ng/!iter sec 0.47 0.05 0.14 0.03 0.39 0.05 0.14 0.03a
Aldosterone pmoi/liter 555 83 139 55 499 83 139 28
Atrial natriuretic peptide pg/mI 18 2 36 6 16 1 43 9
Insulin pmol/liter 210 12 212 24 214 9 204 19
Parathyroid hormone pg/muter 22 3 33 4 24 2 27 3
Endothelinpg/mliter 4.3 0.4 5.2 0.4 3.6 0.5 3.5 0.5
Arginine vasopressin pg/mI 2.2 0.3 2.5 0.4 2.6 0.2 2.0 0.4
Clearance values
Insulin mi/sec 1.62 0.10 1.92 0.22 1.68 0.10 1.60 0.10
p-Aminohippurate mi/sec 9.30 0.60 10.28 0.92 9.28 0.65 8.32 0.77
Baseline values were obtained after 3 days of equilibration on study diet. Values on fludrocortisone were obtained after receiving this agent for
10 days along with either placebo or KCI (potassium chloride).
a Significant (P < 0.05) difference compared to baseline values
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Fig. 3. Serum sodium concentrations in
subjects receiving fludrocortisone along with
either placebo or potassium chloride (KG!)
during 10 day study period. Each symbol
represents an individual subject. P value
represents significant difference between
measurements obtained at baseline (prior to
fludrocortisone administration) and at the
termination of fludrocortisone treatment. Data
were analyzed by paired t-test with each
subject acting as own control.
Table 2. Clinical and biochemical measurements obtained at baseline and after 10 days of fludrocortisone administration
Baseline
Fludrocortisone
+ placebo Baseline
Fludrocortisone
+ KC1
Meanartenal pressure mm Hg 88 2 91 2 88 3 89 1
Serum values
Chloride mmoi/!iter 105 1 106 1 103 1 107 l
Total CO2 mmo!/ljter 26 1 28 1 26 1 26 I
Urea nitrogen mmo!/iiter 6.07 0.70 4.64 0.36a 5.71 0.71 5.35 0.71
Albumin g/!iter 46 1 40 l 44 1 41 ia
Calcium mmoi/iiter 2.27 0.02 2.12 0.02a 2.29 0.02 2.24 0.02k
Phosphate mmol/iiter 1.39 0.13 1.45 0.10 1.39 0.10 1.32 0.06
Baseline values are obtained after 3 days of equilibration on study diet. Values on fiudrocortisone were obtained after receiving this agent for
10 days along with either placebo or KCI (potassium chloride).
a Significant (P < 0.05) difference compared to baseline values
note that despite striking differences in urinary sodium excre-
tion and body weight between placebo and KCI studies the
hormonal responses were very similar. It is likely that the
hormonal measurements lack the sensitivity to discriminate the
differences in ECF volume between the two treatments. This is
particularly likely for renin activity and aldosterone concentra-
tions because the post-study measurements reached their sen-
sitivity level.
Our current findings are in accord with our previous obser-
vations which suggest that dietary potassium restriction induces
sodium retention [6, 10, 11]. We observed a reduction in sodium
excretion within 24 hours after restricting potassium intake [10].
We also observed that dietary sodium restriction induces a
negative sodium balance only if potassium intake is maintained
at normal levels [61. Acute hypokalemia in dogs produced by
hemodialysis induces immediate and striking reduction in uri-
nary sodium excretion [26]. Collectively these studies suggest
that external potassium balance is a pivotal regulator of renal
P=o.o1
1I.
P=O.006
/1' ci,0E
E
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+
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sodium handling. In the current studies, although potassium
administration attenuated the sodium retention produced by
fludrocortisone, this observation does not necessarily establish
a mediator role for potassium depletion in causing sodium
retention. Potassium salts are natriuretic and therefore we
cannot exclude a nonspecific effect of potassium in ameliorating
the mineralocorticoid-jnduced sodium retention. At the doses
employed in the current study the potassium salts may exert a
pharmacologic effect in augmenting sodium excretion.
The mechanism of potassium's ability to modulate sodium
excretion remains to be characterized. Direct tubular effects as
well as the hormonally mediated mechanism need to consid-
ered. The current studies failed to disclose significant changes
in renal hemodynamics or alterations in plasma concentrations
of various hormones which are known to modify urinary
sodium excretion. However, we cannot exclude the possibility
that potassium may alter the renal tubular response to these
agents. The role of other sodium regulating hormones such as
dopamine, kinins and prostaglandins in mediating the effect of
potassium on sodium excretion also requires further study in
humans. Potassium may influence sodium transport by direct
tubular effects. Micropuncture studies indeed suggest that
proximal tubular fluid reabsorption is modulated by acute as
well as chronic alterations in potassium balance [27—311. In
addition, Kirchner observed that chloride reabsorption in the
loop is impaired by potassium loading [32]. The molecular
biology of changes in sodium transport induced by potassium
deserves further investigation.
Potassium may influence sodium transport by virtue of the
cation's effects on Na-H exchanger. Potassium depletion is
associated with a decrease in renal tubular intracellular pH and
an increase in luminal Na-H exchanger activity [33, 34]. The
decrease in intracellular pH is rapidly reversible by the acute
administration of potassium chloride [33]. Kornandakieti, Gret-
kin and Tannen demonstrated an increase in hydrogen ion
secretion in the collecting ducts of potassium depleted rats [35].
Chronic potassium depletion enhances Na-H exchange in rat
cortical brush border membrane vesicles [341. Taken together
these studies suggest that the sodium retentive effects of
potassium depletion may at least in part be related to the
augmentation of tubular Na-H exchange. The role of intra-
cellular acidification [331 and the increase in Na-K-ATPase
[36] produced by potassium depletion in mediating the changes
sodium transport remains unstudied. It is interesting to note
that in the current studies, subjects receiving placebo along
with fludrocortisone manifested an increase in serum bicarbon-
ate concentration, while no such increase was observed while
the subjects received potassium.
Potassium's ability to regulate sodium excretion may carry
pathophysiologic implications. Potassium depletion by lowering
sodium delivery to the distal nephron may limit potassium
secretion at this site and thus assist in potassium conservation.
This prompt adaptation in preserving potassium balance pre-
cedes the advent of more potent regulators such as hypokalemia
and aldosterone suppression. Sodium retentive properties of
potassium depletion may be germane to the pathogenesis of
hypertension. A genetic defect in renal sodium excretion has
been proposed as an initiating event for the development of
hypertension [37, 38]. It is likely that an acquired defect in
sodium excretion such as the one induced by potassium deple-
tion may trigger similar pathophysiologic events and culminate
in hypertension. Indeed, multiple epidemiologic studies con-
ducted in widely divergent geographic locations demonstrate an
inverse correlation between potassium intake and the preva-
lence of hypertension [7]. Although the pathogenesis of potas-
sium-induced changes in blood pressure have not been clearly
elucidated, sodium balance plays an important role. Hypoten-
sive effects of potassium supplementation and the hypertensive
effects of potassium depletion are abrogated by prior sodium
restriction [7]. Fujita and Sato demonstrated that in uninephrec-
tomized rats receiving deoxycorticosterone acetate along with
salt supplements, increasing potassium intake attenuates the
increase in systolic pressure [91.
Hypernatremia associated with hypermineralocorticoid
states has been ascribed to renal concentrating defects pro-
duced by potassium depletion [39]. Dusing et al observed that in
dogs receiving deoxycorticosterone acetate, potassium reple-
tion corrected the polyuria and hypernatremia [40]. It is sug-
gested that enhanced prostaglandin synthesis induced by potas-
sium depletion induces polyuria by inhibiting the tubular action
of vasopressin. Our current observations in humans contrast
with the previous studies in dogs. The increase in serum sodium
concentration was identical in the placebo and potassium
treated groups. However, the magnitude of hypokalemia ob-
served in the current studies is smaller compared to the
hypokalemia noted in the dog studies. We observed no increase
in serum sodium concentration during comparable hypokalemia
induced by dietary potassium restriction [6, 10, 11]. Taken
together our observations in humans suggest that mineralocor-
ticoid-induced hypernatremia in humans occurs independently
of potassium depletion. It is of interest to note that despite an
increase in serum osmolality, plasma concentration of arginine
vasopressin was unaltered during fludrocortisone administra-
tion, An augmentation in osmotic threshold for vasopressin
release has been reported in dogs receiving deoxycorticoste-
rone acetate [41]. The role of volume expansion in mediating
this relative suppression of vasopressin release and the role of
impaired vasopressin release in mediating hypernatremia in
humans requires further study.
In summary, amelioration of hypokalemia during mineralo-
corticoid administration attenuated the sodium retention and
facilitated the escape. These effects of potassium on sodium
excretion occurred independently of the changes in mean
arterial pressure and circulating vasoactive hormone levels.
Mineralocorticoid-induced hypernatremia was unaltered by po-
tassium supplementation. The current observations combined
with the previous studies in our laboratory suggest that potas-
sium balance is a critical determinant of urinary sodium excre-
tion.
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